Primary prevention of sudden cardiac death in heart failure: will the solution be shocking?

Sudden cardiac death (SCD) may occur in as many as 40% of all patients who suffer from heart failure. This review describes the scope of the problem, risk factors for SCD, the effect of medications used in heart failure on SCD and the potential effect of the implantable cardioverter-defibrillator in primary prevention.

[1]  E. Bates.  Effect of amiodarone on mortality after myocardial infarction , 1993 .

[2]  G. Tomaselli,et al.  Long‐Term Follow‐Up of Patients with Nonischemic Dilated Cardiomyopathy and Ventricular Tachyarrhythmias Treated with Implantable Cardioverter Defibrillators , 1991, Pacing and clinical electrophysiology : PACE.

[3]  K. Swedberg,et al.  Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. , 1990, Circulation.

[4]  P. Tchou,et al.  Automatic implantable cardioverter defibrillators and survival of patients with left ventricular dysfunction and malignant ventricular arrhythmias. , 1988, Annals of internal medicine.

[5]  W G Stevenson,et al.  Comparison of frequency of late potentials in idiopathic dilated cardiomyopathy and ischemic cardiomyopathy with advanced congestive heart failure and their usefulness in predicting sudden death. , 1990, The American journal of cardiology.

[6]  J. Caro,et al.  The cost-effectiveness of preventing initial coronary events with pravastatin , 1997 .

[7]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[8]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.

[9]  Eli Warnock,et al.  The effect of diltiazem on mortality and reinfarction after myocardial infarction. , 1989, The New England journal of medicine.

[10]  M. Davies,et al.  Anatomic features in victims of sudden coronary death. Coronary artery pathology. , 1992, Circulation.

[11]  K. Kuck,et al.  Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). , 1994, American heart journal.

[12]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.

[13]  M. Josephson,et al.  Prospective trials of implantable cardioverter defibrillators versus drugs: are they addressing the right question? , 1996, The American journal of cardiology.

[14]  W. Stevenson,et al.  Significance of aborted cardiac arrest and sustained ventricular tachycardia in patients referred for treatment therapy of advanced heart failure. , 1992, American heart journal.

[15]  E. J. Brown,et al.  The effect of digoxin on mortality and morbidity in patients with heart failure. , 1997, The New England journal of medicine.

[16]  F. Harrell,et al.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). , 1997, American heart journal.

[17]  M. Josephson,et al.  Sudden cardiac death in patients with chronic coronary heart disease. , 1992, Circulation.

[18]  J. Cohn,et al.  Prognosis in congestive heart failure. , 1994, Journal of cardiac failure.

[19]  R. Virmani,et al.  Sudden coronary death. Frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. , 1995, Circulation.

[20]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[21]  W. Mckenna,et al.  Usefulness of signal-averaged electrocardiogram in idiopathic dilated cardiomyopathy for identifying patients with ventricular arrhythmias. , 1993, The American journal of cardiology.

[22]  H. Doval,et al.  Randomised trial of low-dose amiodarone in severe congestive heart failure , 1994, The Lancet.

[23]  S. Yusuf,et al.  Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. , 1992, Journal of the American College of Cardiology.

[24]  M. Akhtar,et al.  Nonischemic sudden tachyarrhythmic death in atherosclerotic heart disease. , 1991, Circulation.

[25]  E. Aliot,et al.  A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. , 1995, The New England journal of medicine.

[26]  R. Fogel,et al.  Arrhythmia in Patients with a Cardiomyopathy and Congestive Heart Failure , 1994 .

[27]  D. Milewicz,et al.  Nonbacterial thrombotic endocarditis in three members of a family. , 1997, The New England journal of medicine.

[28]  J R Wilson,et al.  Value of Peak Exercise Oxygen Consumption for Optimal Timing of Cardiac Transplantation in Ambulatory Patients With Heart Failure , 1991, Circulation.

[29]  P. Kudenchuk,et al.  Implantable cardioverter-defibrillator therapy in survivors of out-of-hospital sudden cardiac death without inducible arrhythmias. , 1993, Journal of the American College of Cardiology.

[30]  R. Scully,et al.  Case records of the Massachusetts General Hospital. , 1990 .

[31]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[32]  W. Stevenson,et al.  Inducible ventricular arrhythmias and sudden death during vasodilator therapy of severe heart failure. , 1988, American heart journal.

[33]  M. Pfisterer,et al.  Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS) , 1990, Journal of the American College of Cardiology.

[34]  L. Wilkins.  A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. , 1994, Circulation.

[35]  L. Horowitz,et al.  Prognosis in severe heart failure: relation to hemodynamic measurements and ventricular ectopic activity. , 1983, Journal of the American College of Cardiology.

[36]  J P Miller,et al.  The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. , 1984, Circulation.

[37]  M. Josephson,et al.  Usefulness of programmed stimulation in idiopathic dilated cardiomyopathy. , 1986, The American journal of cardiology.

[38]  R. Goeree,et al.  Cost analysis of dialysis treatments for end-stage renal disease (ESRD). , 1995, Clinical and investigative medicine. Medecine clinique et experimentale.

[39]  S. Connolly,et al.  Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT , 1997, The Lancet.

[40]  A. Camm,et al.  Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT , 1997, The Lancet.

[41]  I. Ringqvist,et al.  Survival of Medically Treated Patients in the Coronary Artery Surgery Study (CASS) Registry , 1982, Circulation.

[42]  M Gent,et al.  Canadian Implantable Defibrillator Study (CIDS): study design and organization. CIDS Co-Investigators. , 1993, The American journal of cardiology.

[43]  G. Murray,et al.  Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators , 1993 .

[44]  M. Packer,et al.  Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. , 1986, Circulation.

[45]  F. Morady,et al.  Electrophysiologic testing in the management of survivors of out-of-hospital cardiac arrest. , 1983, The American journal of cardiology.

[46]  S. Hohnloser,et al.  Mode of death in idiopathic dilated cardiomyopathy: a multivariate analysis of prognostic determinants. , 1988, American heart journal.

[47]  P. Held.  Effects of beta blockers on ventricular dysfunction after myocardial infarction: tolerability and survival effects. , 1993, The American journal of cardiology.

[48]  W. Stevenson,et al.  Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. , 1989, Circulation.

[49]  J. Cohn,et al.  Plasma Norepinephrine, Plasma Renin Activity, and Congestive Heart Failure Relations to Survival and the Effects of Therapy in V‐HeFT II , 1993, Circulation.

[50]  P C Deedwania,et al.  Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. , 1995, The New England journal of medicine.

[51]  F. Tristani,et al.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. , 1991, The New England journal of medicine.

[52]  J. Ruskin,et al.  Influence of the implantable cardioverter/defibrillator on sudden death and total mortality in patients evaluated for cardiac transplantation. , 1995, Circulation.

[53]  Nie Fe.  Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II) , 1990 .

[54]  Z. Blanck,et al.  Therapy of Ventricular Tachycardia in Patients with Nonischemic Cardiomyopathies , 1996, Journal of cardiovascular electrophysiology.

[55]  Erry,et al.  Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. , 1995, The New England journal of medicine.

[56]  S. Yusuf,et al.  Prognosis in Congestive Heart Failure , 1994 .

[57]  J. Cohn,et al.  Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. , 1983, The American journal of cardiology.

[58]  J. Kjekshus.  Arrhythmias and mortality in congestive heart failure. , 1990, The American journal of cardiology.

[59]  D. Zipes,et al.  Results of the international study of the implantable pacemaker cardioverter-defibrillator. A comparison of epicardial and endocardial lead systems. The Pacemaker-Cardioverter-Defibrillator Investigators. , 1995, Circulation.

[60]  J. Fleiss,et al.  Predicting arrhythmic events after acute myocardial infarction using the signal-averaged electrocardiogram. , 1992, The American journal of cardiology.

[61]  S. Gottlieb.  Dead is dead—artificial definitions are no substitute , 1997, The Lancet.

[62]  R. Fogoros,et al.  Long-term outcome of survivors of cardiac arrest whose therapy is guided by electrophysiologic testing. , 1992, Journal of the American College of Cardiology.

[63]  J. Ruskin,et al.  Influence of implantable cardioverter-defibrillators on the long-term prognosis of survivors of out-of-hospital cardiac arrest. , 1993, Circulation.

[64]  A. Jaffe,et al.  Risk factors for sudden death after acute myocardial infarction: two-year follow-up. , 1984, The American journal of cardiology.

[65]  N. Sammel,et al.  Prediction of serious arrhythmic events after myocardial infarction: signal-averaged electrocardiogram, Holter monitoring and radionuclide ventriculography. , 1987, Journal of the American College of Cardiology.

[66]  E. J. Brown,et al.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.

[67]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.

[68]  S. Yusuf,et al.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.

[69]  S. Gottlieb,et al.  Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. , 1989, Journal of the American College of Cardiology.

[70]  G. Sanders,et al.  Cost-Effectiveness of Implantable Cardioverter Defibrillators Relative to Amiodarone for Prevention of Sudden Cardiac Death , 1997, Annals of Internal Medicine.

[71]  M J Reiter,et al.  Effects of mechano-electrical feedback: potential arrhythmogenic influence in patients with congestive heart failure. , 1996, Cardiovascular research.

[72]  J. Langberg,et al.  Survival after implantation of the cardioverter defibrillator. , 1992, The American journal of cardiology.

[73]  W. Zoghbi,et al.  Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy. , 1994, The American journal of cardiology.

[74]  Bertram Pitt,et al.  Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction , 1996, The Lancet.

[75]  C M O'Connor,et al.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. , 1996, The New England journal of medicine.

[76]  Clesham Gj,et al.  Implantable defibrillators in patients with coronary artery disease at high risk for ventricular arrhythmia. , 1997 .

[77]  S L Winters,et al.  A new noninvasive index to predict sustained ventricular tachycardia and sudden death in the first year after myocardial infarction: based on signal-averaged electrocardiogram, radionuclide ejection fraction and Holter monitoring. , 1987, Journal of the American College of Cardiology.

[78]  A. Bayés de Luna,et al.  Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. SSSD Investigators. Spanish Study on Sudden Death. , 1993, The American journal of cardiology.

[79]  S. Dubner,et al.  Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. GESICA-GEMA Investigators. , 1996, Circulation.

[80]  J. Ruskin,et al.  Mortality benefits and the implantable cardioverter-defibrillator. , 1994, Circulation.

[81]  B. Pitt,et al.  Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group. , 1989, Journal of the American College of Cardiology.

[82]  B. Magnani,et al.  The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction , 1995 .

[83]  L. Goldman,et al.  Cost and quality of life: thrombolysis and primary angioplasty. , 1995, Journal of the American College of Cardiology.

[84]  D. Wilber,et al.  Electrophysiological testing and nonsustained ventricular tachycardia. Use and limitations in patients with coronary artery disease and impaired ventricular function. , 1990, Circulation.

[85]  A. Moss,et al.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. , 1996, The New England journal of medicine.